Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 21, 2022 07:30 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning

Outstanding debt reduced by 54% or $388.9 million and annual cash interest expense reduced by 58% or $13.6 million Company well-positioned to drive continued growth in PBC, progress NASH program,...
September 20, 2022 12:45 ET | Source: Intercept Pharmaceuticals, Inc.

Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Combined clinical trial and real-world data with six years of follow-up provides important evidence of efficacy Analysis compares findings from the Phase 3 POISE trial and open-label extension to...
September 07, 2022 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

MORRISTOWN, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel...
August 29, 2022 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Citi 17th Annual BioPharma Conference September 8, 2022

MORRISTOWN, N.J., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
August 19, 2022 07:30 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Announces Repurchase of Convertible Notes

MORRISTOWN, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of...
August 18, 2022 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals to Participate in B. Riley’s PBC Symposium on August 24, 2022

MORRISTOWN, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
August 03, 2022 07:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Worldwide Ocaliva® non-GAAP adjusted net sales in PBC of $100.4 million; U.S. net sales of $71.8 million representing 5% growth over the prior year quarter Company reissues...
July 27, 2022 08:00 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022

MORRISTOWN, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
July 07, 2022 07:30 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

OCA 25 mg met the agreed primary endpoint of improvement in liver fibrosis without worsening of NASH at 18 months (p<0.0001), consistent with the original REGENERATE analysis OCA 25...
July 01, 2022 16:01 ET | Source: Intercept Pharmaceuticals, Inc.

Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S.

MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...